/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Stone Harbor Emerging Markets Total Income Fund

Published

5 years ago

May 30, 2019

Zoltan_Tundik

Reading Time: 4 minutes

Notification of Sources of Distribution

Statement Pursuant to Section 19(a) of the Investment Company Act
of 1940

NEW YORK–(BUSINESS WIRE)–On May 30, 2019, the Stone Harbor Emerging Markets Total Income Fund
(NYSE: EDI) (the “Fund”), a closed-end fund, will pay a monthly
distribution on its common stock of $0.1511 per share to shareholders of
record at the close of business on May 17, 2019. The Fund, acting in
accordance with an exemptive order received from the Securities and
Exchange Commission and with approval of its Board of Trustees, adopted
a managed distribution policy under which the Fund may utilize capital
gains, where applicable, as part of regular monthly cash distributions
to its shareholders. This policy gives the Fund greater flexibility to
realize capital gains and to distribute those gains to shareholders.

The following table sets forth the estimated amounts of the current
distribution and the cumulative distributions paid this fiscal
year-to-date from the sources indicated in the table. In addition, the
table shows the percentages of the total distribution amount per share
attributable to (i) net investment income, (ii) net realized short-term
capital gain, (iii) net realized long-term capital gain and (iv) return
of capital or other capital source. These percentages are disclosed for
the current distribution as well as the fiscal year-to-date cumulative
distribution amount per share for the Fund.


Current Distribution from:
	Per Share ($)	%
Net Investment Income	0.0756	50.03	%
Net Realized Short-Term Capital Gains	0.0000	0.00	%
Net Realized Long-Term Capital Gains	0.0000	0.00	%
Return of Capital or other Capital Source	0.0755	49.97	%
Total (per common share)	0.1511	100.00	%

Fiscal Year-to-Date Cumulative
Distributions from¹:
	Per Share ($)	%
Net Investment Income	0.5295	58.41	%
Net Realized Short-Term Capital Gains	0.0000	0.00	%
Net Realized Long-Term Capital Gains	0.0000	0.00	%
Return of Capital or other Capital Source	0.3771	41.59	%
Total (per common share)	0.9066	100.00	%
________________
¹ The Fund’s fiscal year is December 1 to November 30. Information shown is for the period beginning December 1, 2018.

Shareholders should not draw any conclusions about the Fund’s
investment performance from the amount of this distribution or from the
terms of the Fund’s managed distribution policy.

The Fund estimates that it has distributed more than its income and
net realized capital gains; therefore, a portion of your distribution
may be a return of capital. A return of capital may occur, for
example, when some or all of the money that you invested in the Fund is
paid back to you. A return of capital distribution does not
necessarily reflect the Fund’s investment performance and should not be
confused with ‘yield’ or ‘income.’

The amounts and sources of distributions reported in this 19(a)
Notice are only estimates, may change over time and are not being
provided for tax reporting purposes. The actual amounts and
sources of the amounts for tax reporting purposes will depend upon the
Fund’s investment experience during the remainder of its fiscal year and
may be subject to changes based on tax regulations. The Fund will send
you a Form 1099-DIV for the calendar year that will tell you how to
report these distributions for federal income tax purposes.

Presented below are return figures, based on the change in the Fund’s
Net Asset Value per share (“NAV”), compared to the annualized
distribution rate for this current distribution as a percentage of the
NAV on the last day of the month prior to distribution declaration date.

Fund Performance & Distribution Information

Annualized Distribution Rate as a Percentage of NAV^	16.12	%
Cumulative Distribution Rate as a Percentage of NAV*	8.06	%
Cumulative Total Return as a Percentage of NAV**	6.06	%
Average Annual Total Return***	0.89	%

^ Based on the Fund’s NAV as of April 30, 2019 and the May 30, 2019
distribution.

* Based on the Fund’s NAV as of April 30, 2019 and includes
distributions through May 30, 2019.

** Cumulative Total Return is the percentage change in the Fund’s NAV
including distributions paid and assuming reinvestment of these
distributions for the period December 1, 2018 through April 30, 2019.

*** Average Annual Total Return represents the compound average of the
Annual NAV Total Returns of the Fund for the five year period ending
April 30, 2019. Annual NAV Total Return is the percentage change in the
Fund’s NAV over a year including distributions paid and assuming
reinvestment of these distributions.

While the NAV performance may be indicative of the Fund’s investment
performance, it does not measure the value of a shareholder’s investment
in the Fund. The value of a shareholder’s investment in the Fund is
determined by the Fund’s market price, which is based on the supply and
demand for the Fund’s shares in the open market.

The Fund’s Board of Trustees reviews the amount of any distributions
made pursuant to the Fund’s distribution policy and considers the income
earned and capital gain realized by the Fund, as well as the Fund’s
available capital. The Board of Trustees will continue to monitor the
Fund’s distribution level, taking into consideration, among other
things, the Fund’s net asset value and market conditions. The Fund’s
distribution policy is subject to modification, suspension or
termination by the Board of Trustees at any time, which could have an
adverse effect on the market price of the Fund’s shares. The
distribution rate should not be considered the dividend yield or total
return on an investment in the Fund.

Contacts

Stone Harbor Emerging Markets Total Income Fund (EDI)
John
Dispigno, 1-877-206-0791

Cannabis

Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand

Published

9 hours ago

April 18, 2024

GlobeNewswire

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

2 days ago

April 16, 2024

CISION (PR Newswire)

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the seller.

“With the April 1^st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html